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Summary.-A study of the thymidine labelling index (TLI) of bone marrow blast
cells in 58 untreated patients with acute myelogenous leukaemia showed no
correlation with remission rate but there was a strong correlation between labelling
index and remission length in the 21 patients who achieved remission. The median
remission length of the patients was 33 weeks. Of the 12 patients with initial
labelling indices greater than 10%, only 2 had remissions longer than 33 weeks
whereas 8 of the 9 patients with labelling indices less than 10% had remissions
longer than 33 weeks. No correlation could be found between the degree of cyto-
logical differentiation and remission induction, remission length or survival. No
correlation was found between the TLI and the degree of cytological differentiation.
Age and initial platelet count were confirmed to be important factors influencing
complete remission rate, but these factors did not correlate with remission length.
Sixteen patients had their pretreatment sera assayed for mouse marrow colony
stimulating activity and inhibitor levels butthere was no correlation with subsequent
response to treatment, although the number of patients examined was clearly too
smallfor any definite conclusions tobe drawn.
A NUMBER offactors such as age, initial
platelet count and clinical condition of
the patient at the onset of the disease are
known to be important in relation to
remission rate in patients with acute
myelogenous leukaemia (AML). Fewer
factors havebeenmeasuredwhichcorrelate
with remission length although patients
with acute promyelocytic leukaemia tend
to have longer remissions (Bernard et at.,
1973) and the judicious use of chemo-
therapy or immunotherapy during remis-
sion is now improving remission lengths
in a number of centres (e.g., Clarkson,
1972; Gutterman et al., 1974; Powles
et al., 1973).
Any measurement before treatment
starts, which would give a guide to prog-
nosis and indicate likely remission length,
would therefore be of importance. With
this in mind, a study has been carried out
in which thymidine labelling indices of
the bone marrow blast cells have been
measured and correlated with the degree
of cytological differentiation. The serum
colony stimulating factor and inhibitor
levels have been measured. All these
laboratory findings have been related to
prognosis in patients with AML.
PATIENTS AND METHODS
Patients.-Two hundred and seven
patients were admitted to St Bartholomew's
Hospital with a diagnosis of AML during
1969-73. These patients were treated with a
combination of cytosine arabinoside and
daunorubicin using several dose schedules.
Nearly all patients received 5-day courses in
which daunorubicin was given on the first
day and cytosine arabinoside was given by
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intravenous injection daily on Days 1-5.
Courses were repeated at approximately
10-day intervals. The dose schedules have
been published previously (Crowther et al.,
1970, 1973).
Cytological differentiation.-The diagnosis
of AML was established by examination of
blood and marrow stained by Romanowsky,
PAS and Sudan black techniques (Dacie and
Lewis, 1968). The degree of differentiation
was assessed on Romanowsky stained bone
marrow smears. Only myeloblastic and
myelomonocytic leukaemias were evaluated,
erythroleukaemia, promyelocytic leukaemia
and hypoplastic myeloid leukaemias being
excluded.
Bone marrow nucleated cell counts were
performed on at least 500 cells and the per-
centage of each cell type obtained. The
cases were then divided according to the
degree of differentiation into 3 arbitrary
groups labelled A, B and C. Group A con-
sisted of more than 50% blast cells with no
cytoplasmic granulation. In Group B less
than 50% agranular blast cells were seen
but few cells (less than 10%) beyond the
promyelocyte stage were present. In Group
C less than 50% agranular blast cells were
present but here significant numbers of more
differentiated granulocytes and/or monocytes
were present, myelocytes, metamyelocytes,
segmented neutrophils and/or more mature
monocytoid cells making up more than 20%.
The degree of differentiation was assessed
in 81 patients. In 53 patients the relation-
ship between differentiation and TLI was
also analysed.
Thymidine Labelling Index (TLI).-The
in vitro TLI of blast cells in the marrow was
assessed before any treatment was given in
58 patients. Bone marrow was collected
into heparinized medium 199 (Wellcome)
containing 1-25 jpCi tritiated thymidine/ml
(specific acitivity 5 Ci/mmol) and incubated
for 30 min at 370C. The culture was centri-
fuged at 1000 rev/min for 5 min and smears
were prepared. After air drying and meth-
anol fixation the smears were coated using
K5 emulsion (Ilford). Slides were left for
one week before developing with D19b dev-
eloper (Kodak) and fixing with hypam solu-
tion (Ilford). Depending on the proportion
ofcellslabelled, upto 10,000 cells werecounted
and the labelling index expressed as a per-
centage. Labelled cells oftheerythroid series
and labelled lymphocytes were excluded.
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Colony Stimulating Factor (CSF) and
inhibitor assays.-The methods used were
similar to those previously described by
Bradley and Metcalf (1966). The system
involved the growth ofC57B1 mouse marrow
in 35 mm Falcon plastic Petri dishes using
modified Eagle's medium containing 0.3%
agar.
The serum inhibitor levels were assayed
using a standard "active human serum"
(AHS). AHS was prepared from a mixture
of calcium phosphate urine extract (Stanley
et al., 1972) with a dialysed serum obtained
from a patient known to have high levels
ofCSF. A concentration ofAHS was chosen
which gave approximately 50 colonies per
plate. Inhibitor levels were measured by
pipetting 0-1 ml of the test sera into a dish
with 0 05 ml of AHS.
One ml of modified Eagle's medium con-
taining 75,000 marrow cells and 0.3% agar
was then added to each plate and incubated
in 5% C02 for 7 days at 370C. At this time
the number of colonies containing more than
50 cells were counted using a Zeiss dissecting
microscope at x 15 magnification.
The CSF levels were measured using
dialysed serum in order to remove inhibitory
material. In this assay 0.1 ml of serum was
added to the plate containing mouse marrow
cells without the addition of AHS. All sera
were tested in duplicate and 6 positive con-
trol plates with AHS alone and 6 negative
control plates with no active sera were set
up during each experiment.
CSF =colony count
inhibitor ( +ve control count) - (test count) x 100 (+ve control count)
RESUMLbS
Factors related to remi8sion rate
Age was the most important single
factor influencing remission rate. The
clear relationship between age and res-
ponse to induction chemotherapy is seen
in Table I. Remission induction rate was
almost twice as great in patients younger
than 60 years than it was in patients older
than this.
The initial platelet count was also of
some importance (Table II). Only 9 of
33 patients presenting with platelet counts
less than 20,000/ pl achieved complete
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TABLE I. Relationship between Age and
Remission Rate
Complete Correctedl
No. of Iremission No. not remission
Age patients (G%) treate(d (%)
10-9 6 83 0 83
20-29 23 52 1 54
30-39 25 48 1 50
40-49 36 42 2 44
50 59 56 41 3 43
60-69 49 28 4 31
70-79 12 8 2 10
indices of 10% or less. There was no
significant relation between the degree
of cytological differentiation and the
remission rate (Table IV). No signifi-
cant correlation was found between the
TLI and the degree of cytological differ-
entiation (Fig. 2), although there was a
suggestion that with larger numbers of
cases, increasing differentiation might
have correlated with a decrease in TLI.
TABLE II.-Relationship between Initial
Platelet Count and Remission Rate
Iiitial
platelet
count
(per ,ul)
<20000
> 20000
No. of
patients
33
174
Complete
remissionl
73
0%
27
42
TABLE III.-Relationship between Re-
mission Rate and Initial Blast Count
Initial
blast
count
(per ul)
<100
100-2000
2000+
No. of
patients
45
6 1
101
Complete
remission
22
20
40
49
33
40
remissions compared with 73 of 174
patients presenting with platelet counts
higher than this. The reason for this is
unclear since haemorrhage was an uncom-
mon cause ofdeath and could be prevented
or arrested using fresh platelet trans-
fusions. It may be that the low platelet
counts were a reflection of poor normal
marrow reserve, which was associated with
a slower return to normal following
induction chemotherapy.
The initial blast count in the blood did
not appear to affect the remission rate
significantly although there was a slight
tendency for those with very few blast
cells to have a higher remission rate
(Table III).
The TLI of the blast cells in the mar-
row had no apparent relation to the rem-
ission induction rate (Fig. 1). There
were 11 remissions in 29 patients with
labelling indices greater than 10% and
9 remissions in 29 patients with labelling
TABLE IV.-Relation between Differentia-
tion and Remission Rate
No. of patients
(No. achieving
Cytological remission/ Remission
(lifferentiation total) I-ate %
A 12/28 43
B 18/29 55
C 10/24 46
B- + C 28/53 53
Of 19 normal control sera studied for
mouse marrow colony stimulatingactivity,
all were in the range of 0-5 u. Pretreat-
ment sera from 16 patients were assayed
for CSF and of these, 6 had normal levels
(0-6 u), and 10 had high levels (12-40 u).
Of the 6 with normal levels of CSF, 5
had remission induction treatment with
daunorubicin and cytosine arabinoside
and 4 achieved a complete remission
Ofthe 10 with high levels ofCSF, following
treatment with daunorubicin and cytosine
arabinoside, 6 achieved a complete remis-
sion. There was no significant difference
in the survival of patients from the 2
groups (Table V).
Nineteen normal control sera were
assayed for inhibitory activity against
mouse marrow colony growth. Seven-
teen had inhibitory levels greater than
45%; 2 had lower levels of inhibitory
activity (25% and 0%O). Pretreatment
sera from 14 patients with AML were also
assayed for inhibitory activity. Six
had normal levels (greater than 500%
inhibition) and 8 had sub-normal levels
(0-23% inhibition). Ofthe 6 with normal
levels, 4 achieved a complete remission
after treatment with daunorubicin and
cytosine arabinoside. Of the 8 with low
levels, 5 achieved a complete remission.PROGNOSIS IN ADULTS WITH ACUTE MYELOGENOUS LEUKAEMIA
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FiG. I.-The relationship between thymidine labelling index of marrow blast cells before treatment
and response to in-iduction chemotherapy in AML.
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FIG. 2.-Relationship between cytological differentiation and the thymidine labellirng index of bone
marrow blast cells.
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TABLE V.-Levels of Colony Stimulating Factor(s) in the Sera of Untreated Patients
Normal levels (< 10 u)
Diagnosis
AML
EL
AML
AML
AML
AML
CSF
level
4
1
0
3
5
6
Remission
No
Yes
Yes
Yes
Yes
Survival
(weeks)
1
104+
26
72+
12
118+
High levels (> 10 u)
CSF Survival
Name Diagnosis level Remission (weeks)
PB AMML 40 No 6
PBr AML 18 Yes 158
BB AML 22 Yes 23
LB AMML 12 No 16
PC AMML 13 No 13
BE AML 19 Yes 44
VH AML 22 No 12
IM AMI, 40 Yes 62-+
SO AMML 12 Yes 47
AP AML 20 Yes 26
AML-Acute myeloblastic leukaemia
AMML-Acute myelomonoblastic leukaemia
EL-Erythroleukaemia
TABLE VI.-Levels of Inhibitor(s) of Colony Formation in the Sera of Untreated Patients
Ni
JB
BE
YH
IM
p
S
Normal levels (<45%)
% Survival
Eme Diagnosis Inhibn Remission (weeks)
AML 53 No 1
AML 65 Yes 44
AML 88 No 12
AML 63 Yes 62+
AMIL 89 Yes 26
AML 81 Yes 12
Low levels (>45%)
I
Name
IB
PBr
KB
LB
MB
B
PC
So
Diag nosis
EL
AML
AML
AMML
AML
AML
AMML
AMML
Inhibn Remission
0
0
22
0
0
23
0
0
Yes
Yes
No
Yes
No
No
Yes
Survival
(weeks)
104+
158
26
16
118+
16
13
47
AML-Acute myeloblastic leukaemia
AMML-Acute myelomonoblastic leukaemia
EL-Erythroleukaemia
There was no significant difference in the
survival of patients from the 2 groups
(Table VI).
Factors related to remission length
Of the many factors studied at the
time of presentation in acute myeloblastic
leukaemia and acute myelomonoblastic
leukaemia, there was only one (the pre-
treatment thymidine labelling index of
blast cells in the marrow) which showed
a strong correlation with remission length
(Fig. 3). Twenty-one patients who
achieved remission had the TLI measured
on the pretreatment bone marrow. The
median remission length of these patients
was 33 weeks. Of the 12 patients with
initial labelling indices greater than 10%
only 2 had remissionslongerthan 33weeks,
whereas 8 of the 9 patients with labelling
indices less than 100% had long remissions.
Figure 4 shows the rather poor overall
correlation between TLI and survival.
The most important single factor influ-
encing survival was whether complete
remission was achieved or not. In our
series this was not related to TLI and
early deaths occurred in both high and
low thymidine labelling groups. Never-
theless, 9 of the 12 patients who survived
more than 12 months had a low TLI.
Age, initial platelet count, initial blast
count in the blood, degree of cytological
differentiation, CSF serum levels and
colony inhibitor levels did not show a
correlation with remission length. There
was a suggestion, however, that Groups
B and C survived longer than Group A,
Name
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MBPROGNOSIS IN ADULTS WITH ACUTE MYELOGENOUS LFITJKAEMIA
60
;Z 50
I-
z
IL
0
tD 30
x
0
z
z , 20
Ji
K)
0 3 6 9 12 15 18 21 24 27 301
* R*elapsed
*Still in Remission
36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90
FIRST REMISSION in WEEKS
FIG. 3.-The relationship between thymidine labelling index of marrow blast cells before treatment
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FIG. 4.-The relationship between thymidine labelling index of marrow blast cells before treatment
and survival in AML.
but this difference was not significant.
Inhibitor and CSF titres were measured
in 90 sera from 25 patients with AML at
different times during the course of their
illness. Figure 5 shows that abnormal
CSF and inhibitor levels were found in the
majority of AML sera tested. The levels
were of no apparent prognostic value.
Abnormal levels of both inhibitor and
CSF persisted in several patients in spite of
continuing remissions of long duration.
In this situation, the treatment of early
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FIG. 5.-Levels of inhibitor and colony stimulating factor in the sera ofnormal controls and patients
with AML testing during the course of their disease.
tumours of small mass may result in a
dose related increase in survival, whereas
late tumours with slower doubling times
may have a short survival time with simi-
lar chemotherapy.
Burke and Owens (1971) studied thy-
midine labelling indices of bone marrow
blast cells in 19 patients with AML before
treatment. Tumour cells in the aspirates
from patients who later entered complete
remission had comparatively highlabelling
indices. Seven of 10 patients with label-
ling indices greater than 10% achieved
remission compared with only 3 of 9
patients with indices less than 10%.
Vogler, Cooper and Groth (1974) studied
15 cases of AML using similar methods
and found that the 9 responders had a
mean labelling index of 8.2% and the 6
non-responders 4 0%. Hart, Freireich
and Frei (1974) have also provided data
suggesting that the remission response to
treatment in patients with AML is related
to the thymidine labelling index. Our
data show no relationship between the
incidence of complete remission and TLI.
There was no relationship between the
TLI of blast cells in the marrow of 58
patients before treatment and the remis-
sion rate following treatment with inter-
mittent courses of daunorubicin and cyto-
sine arabinoside. The reason why TLI
and remission incidence did not show a
positive correlation in our series is not
clear. Our own studies have shown that
the TLI can vary markedly following
chemotherapy in AML (Crowther, 1971).
Others have shown similar effects (Burke
and Owens, 1971; Vogler et al., 1974).
Patients with a low initial TLI can have
marked elevation in TLI following cyto-
sine arabinoside, and this may be respon-
sible for an improvement in tumour cell
kill following phase dependent chemo-
therapy.
In spite of the lack of correlation
between TLI and remission rate, there
was an important correlation between
the labelling inldex and the length of
remission. The median remission length
for the group of 21 patients studied was
33 weeks. Eight of the 9 patients with
labelling indices lower than 10% had
remissions longer than this, whereas only
2 of the 12 patients with higher labelling
indices had remission lengths longer than
the median. Hartetal. (1974) showedthat
the TLI in their group of patients was
related to survival. In our series only
the survival of patients who achieved
remission could be correlated with the
TLI.
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Although there are several factors
which are known to influence remission
rate in patients with AML, such as initial
platelet count, age, clinical condition
and to some extent the initial peripheral
blast count, these factors do not appear
to influence the remisssion length apprec-
iably. The initial TLI does provide an
estimate of the likely remission length and
is therefore of some importance when
studying the effects of chemotherapy or
immunotherapy on the duration of remis-
sion. A group of patients weighted in
thedirection ofhighTLIwouldbeexpected
to do less well than a group with a lower
TLI. This factor should be taken into
consideration for proper analysis of thera-
peutic trials designed to prolong remissions
in this disease.
It may be that tumours with high
initial TLI will regenerate faster following
induction ofremission with chemotherapy.
The data presented here are consistent
with this hypothesis but these studies
take no account of cell loss from the
leukaemic cell population and a high
TLI cannot necessarily be equated with a
high actual tumour doubling time.
Although Brincker (1973) suggested that
the degree of cytological differentiation
could be correlated with remission rate,
only small numbers of patients were
studied. No such correlation could be
found in this study.
Although the validity of using mouse
marrow cells to measure human CSF and
inhibitor levels could be questioned, the
method is satisfactory in that spontaneous
colony formation is not observed and
mouse cells respond well to CSF from
most species (Moore and Williams, 1972).
Serum and urine CSF levels measured
using these methods have been shown to
be elevated at some stage of the disease
in all AML patients (Robinson and Pike,
1970; Metcalf et al., 1971. Our findings
of increased CSF levels and reduced
amounts of inhibitor in the sera of un-
treated patients with AML confirm this
work. The pretreatment levels, however,
appear to have no correlationwithresponse
to treatment or duration ofanysubsequent
remission in our series of patients. Our
work on the growth of AML cells in
suspension culture from the blood has
shown that excellent short-term growth
can be achieved in nearly all patients
studied without the addition of CSF
(Balkwill, Pindar and Crowther, 1974).
The cultured AML cells in this system did
not mature beyond the promyelocyte
stage. Their growth and maturation
defect is therefore unlikely to bedependent
upon the high CSF and low inhibitor in
vivo levels which are present before treat-
ment. High CSF levels and low inhibitor
levels probably provide a greater stimulus
to the normal granulocyte pool and these
changes observed in AML patients are
mofe likely to be a consequence than a
cause of the leukaemic process. Recently
however, Metcalf et al. (1974) have shown
that AML cells may be slightly more
responsive than normal to low levels of
CSF. These would give AML cells a
growth advantage in this situation. A
study of local growth regulating factors in
the bone marrow would be relevant to
this problem and could provide further
information on the possible role of leuko-
poietic regulators in the leukaemic process.
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